• 83articles
    Sort by
    Latested
    Open Access
    Review
    Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it
    The antiapoptotic B cell lymphoma-2 (Bcl-2) family members are apical regulators of the intrinsic pathway of apoptosis that orchestrate mitochondrial outer membrane permeabilization (MOMP) through i...
    Prasad Sulkshane, Tanuja Teni
    Published: May 24, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00083
    Viewed:89
    Downloaded:9
    Open Access
    Review
    Antibody-drug conjugates: beyond current approvals and potential future strategies
    The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits...
    Siddharth Menon ... Hui K. Gan
    Published: April 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00082
    Viewed:359
    Downloaded:31
    Open Access
    Perspective
    Endocrine resistant breast cancer: brain metastasis
    Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to ...
    Matthew Willman ... Brandon Lucke-Wold
    Published: April 26, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00081
    Viewed:259
    Downloaded:27
    Open Access
    Review
    Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
    Improving the survival of patients with cholangiocarcinoma (CCA) has long proved challenging, although the treatment of this disease nowadays is on advancement. The historical invariability of survi...
    Marianeve Carotenuto ... Nicola Normanno
    Published: April 26, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00079
    Viewed:232
    Downloaded:10
    Open Access
    Original Article
    The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer
    Aim: Zinc is a key secondary messenger that can regulate multiple signalling pathways within cancer cells, thus its levels need to be strictly controlled. The Zrt, Irt-like protein (ZIP, SLC39A) ...
    Samuel Jones ... Kathryn M. Taylor
    Published: April 26, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00080
    Viewed:241
    Downloaded:25
    Open Access
    Review
    Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
    The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a...
    Aglaia Skolariki ... Simon Lord
    Published: April 24, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00078
    Viewed:237
    Downloaded:19
    Open Access
    Review
    Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Antibody-drug conjugates (ADCs) represent a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies to the cytotoxicit...
    Marta Nerone ... Ilaria Colombo
    Published: April 19, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00077
    Viewed:304
    Downloaded:20
    Open Access
    Review
    Yeast as a tool to decipher the molecular mechanisms underlying the functions of Bcl-2 family
    The budding yeast Saccharomyces cerevisiae, a favorite model in biology, does not contain any protein of the Bcl-2 family. From initial experiments with two-hybrid systems to the heterologous expression of human Bcl-2 family members, and the characterization of several forms of yeast programmed cell death, ...
    Stéphen Manon
    Published: April 02, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00076
    Viewed:384
    Downloaded:30
    Open Access
    Review
    Polyester materials for mRNA delivery
    Messenger RNA (mRNA) has recently made important progress in clinical implementation, offering a promising therapeutic option for infectious disease and cancer. However, the nature of mRNA molecules...
    Wang Chen ... Dandan Zhu
    Published: March 11, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00075
    Viewed:331
    Downloaded:51
    Open Access
    Review
    Targeting the two-pore channel 2 in cancer progression and metastasis
    The importance of Ca2+ signaling, and particularly Ca2+ channels, in key events of cancer cell function such as proliferation, metastasis, autophagy and angiogenesis, has recently begun to be appreciated. Of particular note are two-pore channels (TPCs), a group of recently identified Ca2+-channels, located within the endolysosomal system. ...
    Kathryn A. Skelding ... Lisa F. Lincz
    Published: February 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00072
    Viewed:366
    Downloaded:22
    Open Access
    Case Report
    Liver venous deprivation for resection of advanced hilar cholangiocarcinoma—a case report and review of the literature
    Hilar cholangiocarcinoma is a rare primary malignancy associated with a dismal prognosis. Currently, complete extended right or left-sided hepatectomy is the primary curative therapy. Achieving a ne...
    Radoslava Stoyanova ... Alexander Klaus
    Published: February 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00073
    Viewed:230
    Downloaded:40
    Open Access
    Original Article
    Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
    Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes that can occur in signaling pathways after endocrine manipulation. Methods: The MCF7 breas...
    Kate M. Moore ... Simon P. Langdon
    Published: February 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00074
    Viewed:422
    Downloaded:58
    Open Access
    Review
    New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
    Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characterist...
    Kira-Lee Koster ... Markus Joerger
    Published: February 24, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00069
    Viewed:398
    Downloaded:35
    Open Access
    Original Article
    B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells
    Aim: T-helper cells could play an important role in the pathogenesis of chronic lymphocytic leukemia (CLL), a common B-cell neoplasm. Although CLL cells can present soluble antigens targeted from...
    Annabel R. Minton ... Graham Packham
    Published: February 25, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00070
    Viewed:407
    Downloaded:32
    Open Access
    Review
    Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics
    During the past two decades, tremendous progress has been made in the dendrimer-based delivery of therapeutic molecules including, for instance, small molecules, macromolecules, and genes. This revi...
    Serge Mignani ... Jean-Pierre Majoral
    Published: February 25, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00071
    Viewed:347
    Downloaded:17
    Open Access
    Original Article
    Bcl-2-like protein-10 increases aggressive features of melanoma cells
    Aim: B-cell lymphoma-2 (Bcl-2)-like protein-10 (Bcl2L10) is the less studied member of Bcl-2 family proteins, with the controversial role in different cancer histotypes. Very recently, Bcl2L10 ex...
    Donatella Del Bufalo ... Simona D’Aguanno
    Published: January 30, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00068
    Viewed:608
    Downloaded:55
    Open Access
    Review
    Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
    Targeted immunotherapy has arisen over the past decade to the forefront of cancer care. Notably, targeted therapies such as antibody-drug conjugates (ADCs) are becoming more recognized for a novel a...
    Monique Hartley-Brown, Paul Richardson
    Published: January 14, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00067
    Viewed:515
    Downloaded:74
    Open Access
    Review
    Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women
    Obesity has dramatically increased over the past fifty years. In the last decade, it has been noted that augmented body mass, metabolic abnormalities, and the relevant “obese”...
    Katarzyna Rygiel
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00066
    Viewed:343
    Downloaded:49
    Open Access
    Original Article
    The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
    Aim: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targ...
    Chiara Tarantelli ... Francesco Bertoni
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00065
    Viewed:826
    Downloaded:58
    Open Access
    Original Article
    Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
    Aim: Direct analytical comparison of two major drug-linkers in the antibody-drug conjugate (ADC) field was conducted. Methods: Four different analytical methods [AlogP calculation, reverse phase (RP) high-performance liquid chromatography (HPLC; RP-HPLC), size exclusion chromatography HPLC (SEC-HPLC), and differential scanning calorimetry (DSC)] were tested for this comparison....
    Tomohiro Fujii ... Yutaka Matsuda
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00064
    Viewed:578
    Downloaded:56
    Open Access
    Original Article
    Alterations in the Ca2+ toolkit in oesophageal adenocarcinoma
    Aim: To investigate alterations in transcription of genes, encoding Ca2+ toolkit proteins, in oesophageal adenocarcinoma (OAC) and to assess associations between gene expression, tumor ...
    Alana L. Cutliffe ... John J. Mackrill
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00063
    Viewed:378
    Downloaded:35
    Open Access
    Review
    Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
    The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In r...
    Stefano Cavalieri ... Laura D. Locati
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00062
    Viewed:683
    Downloaded:57
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the...
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00061
    Viewed:855
    Downloaded:97
    Open Access
    Review
    Proteolysis-targeting chimeras and their implications in breast cancer
    Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estro...
    Angeles C. Tecalco-Cruz ... Alberto Rojas-Ochoa
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00060
    Viewed:583
    Downloaded:51
    Open Access
    Review
    A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identifi...
    Giacomo Aimar ... Massimo Di Maio
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00056
    Viewed:590
    Downloaded:62
    Open Access
    Review
    Targeted therapy of multiple myeloma
    Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells (PCs) and is characterized by uncontrolled proliferation of PCs and excessive production of specific types of im...
    Shan Zhou, Renxi Wang
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00057
    Viewed:417
    Downloaded:34
    Open Access
    Original Article
    Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center
    Aim: Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensu...
    Maristella Bungaro ... Silvia Novello
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00058
    Viewed:383
    Downloaded:29
    Open Access
    Review
    Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
    Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizin...
    Alfredo Rossi ... Marta Carlesimo
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00059
    Viewed:504
    Downloaded:24
    Open Access
    Review
    Current options and future directions of systemic therapy for advanced biliary tract cancer
    Biliary tract cancers (BTCs) are aggressive tumors arising from different portions of the biliary tree and classified according to the anatomical location in intrahepatic (i) cholangiocarcinoma (CCA...
    Maria Giuseppina Prete ... Lorenza Rimassa
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00054
    Viewed:895
    Downloaded:59
    Open Access
    Review
    Targeting protein kinase CK2 in the treatment of cholangiocarcinoma
    Cholangiocarcinoma (CCA) is a disease with a very poor prognosis and limited treatment options. Although targeted therapies directed towards specific mutations found in CCA are becoming available an...
    Padma-Sheela Jayaraman, Kevin Gaston
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00055
    Viewed:654
    Downloaded:46
    Open Access
    Review
    A novel strategy for treating cancer: understanding the role of Ca2+ signaling from nociceptive TRP channels in regulating cancer progression
    Cancer is an aging-associated disease and caused by genomic instability that is driven by the accumulation of mutations and epimutations in the aging process. Although Ca2+ signaling, re...
    Wen-Li Hsu ... Etsuro Ito
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00053
    Viewed:676
    Downloaded:52
    Open Access
    Review
    Role of estrogen receptor coregulators in endocrine resistant breast cancer
    Breast cancer (BC) is the most ubiquitous cancer in women. Approximately 70–80% of BC diagnoses are positive for estrogen receptor (ER) alpha (ERα). The steroid ho...
    Kristin A. Altwegg, Ratna K. Vadlamudi
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00052
    Viewed:1313
    Downloaded:74
    Open Access
    Review
    The promising potential of piperlongumine as an emerging therapeutics for cancer
    In spite of the immense advancement in the diagnostic and treatment modalities, cancer continues to be one of the leading causes of mortality across the globe, responsible for the death of around 10...
    Dey Parama ... Ajaikumar B. Kunnumakkara
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00049
    Viewed:1110
    Downloaded:83
    Open Access
    Review
    The evolving role and utility of off-label drug use in multiple myeloma
    The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 1...
    James H Stoeckle ... Gareth J Morgan
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00050
    Viewed:1513
    Downloaded:33
    Open Access
    Review
    Does the gut microbiome environment influence response to systemic breast cancer treatment?
    The gut microbiome is a novel player in the pathogenesis and treatment of breast cancer. The term “microbiome” is used to describe the diverse community of micro-organisms exis...
    Eilidh Bruce ... Beatrix Elsberger
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00051
    Viewed:607
    Downloaded:38
    Open Access
    Original Article
    The effect of iron on the expression levels of calcium related gene in cisplatin resistant epithelial ovarian cancer cells
    Aim: Anticancer drugs (chemotherapeutics) used in cancer treatment (chemotherapy) lead to drug resistance. This study was conducted to investigate the possible effect of iron on calcium homeostasis...
    Bahire Kucukkaya ... Leman Yalcintepe
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00048
    Viewed:398
    Downloaded:33
    Open Access
    Review
    Targeting cytoskeletal phosphorylation in cancer
    Phosphorylation of cytoskeletal proteins regulates the dynamics of polymerization, stability, and disassembly of the different types of cytoskeletal polymers. These control the ability of cells to m...
    Clara Llorente-González ... Miguel Vicente-Manzanares
    Published: June 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00047
    Viewed:530
    Downloaded:51
    Open Access
    Review
    Advances in the study of cancer metastasis and calcium signaling as potential therapeutic targets
    Metastasis is still the primary cause of cancer-related mortality. However, the underlying mechanisms of cancer metastasis are not yet fully understood. Currently, the epithelial-mesenchymal transit...
    Chaochu Cui ... Xianwei Wang
    Published: June 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00046
    Viewed:822
    Downloaded:92
    Open Access
    Original Article
    Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
    Aim: The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of T...
    Edoardo Lenci ... Rossana Berardi
    Published: June 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00043
    Viewed:798
    Downloaded:59
    Open Access
    Case Report
    Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type
    Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline alterations in mismatch repair (MMR) genes leading to increased risk of colon cancer as well as other cancer types. N...
    Elena Maccaroni ... Rossana Berardi
    Published: June 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00044
    Viewed:904
    Downloaded:43
    Open Access
    Review
    Overview of Ca2+ signaling in lung cancer progression and metastatic lung cancer with bone metastasis
    Intracellular Ca2+ ions that are thought to be one of the most important second messengers for cellular signaling, have a substantial diversity of roles in regulating a plethora of funda...
    Manh Tien Tran
    Published: June 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00045
    Viewed:831
    Downloaded:31
    Open Access
    Original Article
    Understanding doxorubicin associated calcium remodeling during triple-negative breast cancer treatment: an in silico study
    Aim: Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer with high heterogeneity, rapid progression, and paucity of treatment options. The most effective chemotherape...
    Garhima Arora ... Samrat Chatterjee
    Published: April 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00042
    Viewed:1047
    Downloaded:84
    Open Access
    Original Article
    Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
    Aim: Nuclear factor erythroid 2-related factor 2 (NRF2) is a key component in the cell’s response to oxidative and electrophilic stress and is a transcription factor regulating the expre...
    Ibrahim H. Kankia ... Yusuf Y. Deeni
    Published: April 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00040
    Viewed:576
    Downloaded:43
    Open Access
    Editorial
    Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?
    Carminia Maria Della Corte ... Floriana Morgillo
    Published: April 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00041
    Viewed:501
    Downloaded:11
    Open Access
    Review
    Liquid biopsy in NSCLC: a new challenge in radiation therapy
    Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide. To date, tissue biopsy has been the gold standard for the diagnosis and the identification of specific mole...
    Annarita Perillo ... Ida Rosalia Scognamiglio
    Published: April 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00038
    Viewed:765
    Downloaded:28
    Open Access
    Review
    Gastrointestinal disorders as immune-related adverse events
    Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel dr...
    Daniele Balducci ... Luca Maroni
    Published: April 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00039
    Viewed:553
    Downloaded:14
    Open Access
    Review
    Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
    About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification...
    Paolo Tarantino ... Giuseppe Curigliano
    Published: April 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00037
    Viewed:2270
    Downloaded:129
    Open Access
    Review
    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
    Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseas...
    Valeria Cognigni ... Rossana Berardi
    Published: April 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00036
    Viewed:1470
    Downloaded:77
    Open Access
    Review
    Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
    Multiple myeloma (MM), the second most common hematologic cancer, is caused by accumulation of aberrant plasma cells in the bone marrow. Its molecular causes are not fully understood and its great h...
    Sara Ovejero, Jerome Moreaux
    Published: February 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00034
    Viewed:1452
    Downloaded:41
    Open Access
    Review
    Aptamers and antibodies: rivals or allies in cancer targeted therapy?
    The goal of an efficacious cancer therapy is to specifically target diseased cells at high accuracy while sparing normal, healthy cells. Over the past three decades, immunotherapy, based on the use ...
    Lisa Agnello ... Laura Cerchia
    Published: February 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00035
    Viewed:946
    Downloaded:51
    Open Access
    Review
    Immunotherapy in gynecological cancers
    Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to e...
    Domenica Lorusso ... Giovanni Scambia
    Published: February 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00033
    Viewed:759
    Downloaded:28
    Open Access
    Review
    Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy
    The occurrence of phenotype switch from an epithelial to a mesenchymal cell state during the activation of the epithelial mesenchymal transition (EMT) program in cancer cells has been closely associ...
    Viviana De Rosa ... Francesca Iommelli
    Published: February 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00032
    Viewed:639
    Downloaded:27
    Open Access
    Review
    Emerging role of pioneer transcription factors in targeted ERα positive breast cancer
    Transcription factors (TFs) are modular protein groups that preferably bind to DNA sequences and guide genomic expression through transcription. Among these key regulators, “pioneer facto...
    Honey Pavithran, Ranjith Kumavath
    Published: February 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00031
    Viewed:949
    Downloaded:34
    Open Access
    Review
    Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
    The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in p...
    Luca Cantini ... Rossana Berardi
    Published: February 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00030
    Viewed:867
    Downloaded:28
    Open Access
    Letter to the Editor
    Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particula...
    Marta Brambilla ... Mario Occhipinti
    Published: December 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00027
    Viewed:1164
    Downloaded:26
    Open Access
    Review
    Circulating biomarkers in malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have ...
    Giuseppe Viscardi ... Giulia Galli
    Published: December 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00028
    Viewed:1353
    Downloaded:47
    Open Access
    Review
    An overview of immune checkpoint inhibitors in breast cancer
    Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-nega...
    Federica Miglietta ... Nicla La Verde
    Published: December 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00029
    Viewed:2093
    Downloaded:91
    Open Access
    Review
    An overview of the potential anticancer properties of cardamonin
    Cancer is one of the leading causes of mortality, contributing to 9.6 million deaths globally in 2018 alone. Although several cancer treatments exist, they are often associated with severe side effe...
    Shanaya Ramchandani ... Manoj Garg
    Published: December 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00026
    Viewed:1443
    Downloaded:38
    Open Access
    Review
    Targeting transcription factors in cancer drug discovery
    Cancer drug discovery is currently dominated by clinical trials or clinical research. Several potential drug candidates have been brought into the pipeline of drug discovery after showing very promi...
    Partha Mitra
    Published: December 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00025
    Viewed:1742
    Downloaded:113
    Open Access
    Review
    Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
    Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene add...
    Marialucia Iacovino ... Francesca Sparano
    Published: December 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00024
    Viewed:1133
    Downloaded:47
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b...
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00023
    Viewed:2267
    Downloaded:149
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains...
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Published: October 30, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00019
    Viewed:1462
    Downloaded:42
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c...
    Giulia Meoni ... Angela Stefania Ribecco
    Published: October 30, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00022
    Viewed:1222
    Downloaded:29
    Open Access
    Original Article
    Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
    Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamox...
    Milene Volpato ... Valerie Speirs
    Published: October 30, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00021
    Viewed:1612
    Downloaded:33
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” ...
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00018
    Viewed:11837
    Downloaded:1653
    Open Access
    Review
    Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
    Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small ...
    Giovanni Vicidomini ... Mario Santini
    Published: October 30, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00020
    Viewed:919
    Downloaded:22
    Open Access
    Review
    Possible applications of salvianolic acid B against different cancers
    Cancer is the second death causing disease worldwide after cardiovascular abnormalities. The difficulty in treating tumor cells with more precise targeted interventions and recurrence of cancer afte...
    Iram Shahzadi ... Reza Mohammadinejad
    Published: August 31, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00014
    Viewed:1236
    Downloaded:24
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified...
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00017
    Viewed:2974
    Downloaded:177
    Open Access
    Review
    Future directions and management of liquid biopsy in non-small cell lung cancer
    Lung cancer represents the world’s most common cause of cancer death. In recent years, we moved from a generic therapeutic strategy to a personalized approach, based on the molecular char...
    Alessia Maria Cossu ... Marco Bocchetti
    Published: August 31, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00015
    Viewed:1510
    Downloaded:46
    Open Access
    Commentary
    Circulating cancer stem cells: an interesting niche to explore
    Federica Papaccio
    Published: August 31, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00016
    Viewed:1307
    Downloaded:49
    Open Access
    Review
    A brief overview of antitumoral actions of bruceine D
    Cancer remains the second leading cause of mortality globally. In combating cancer, conventional chemotherapy and/or radiotherapy are administered as first-line therapy. However, these are usually a...
    Zi Wayne Sin ... Manoj Garg
    Published: August 31, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00013
    Viewed:1350
    Downloaded:40
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell ...
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00009
    Viewed:5092
    Downloaded:216
    Open Access
    Review
    An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen)
    Tanshinone is a herbal medicinal compound described in Chinese medicine, extracted from the roots of Salvia miltiorrhiza (Danshen). This family of compounds, including Tanshinone IIA and Tanshinone...
    Irum Naz ... Kwang Seok Ahn
    Published: June 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00010
    Viewed:1903
    Downloaded:61
    Open Access
    Review
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the...
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00012
    Viewed:2014
    Downloaded:44
    Open Access
    Review
    Integration of PARP-inhibitors in ovarian cancer therapy
    Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting....
    Antonella Pietragalla ... Gennaro Daniele
    Published: June 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00011
    Viewed:1133
    Downloaded:25
    Open Access
    Case Report
    Multiple adverse drug reactions during all-trans retinoic acid treatment for acute promyelocytic leukemia: differentiation syndrome, bradycardia, intestinal necrosis
    All-trans retinoic acid (ATRA) induces complete remission in a high proportion of acute promyelocytic leukemia (APL). Nevertheless it is be associated with adverse drug reactions that might be life-...
    Valeria Ferla ... Nicola Stefano Fracchiolla
    Published: April 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00007
    Viewed:1252
    Downloaded:13
    Open Access
    Review
    Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advance...
    Giuliano Palumbo ... Alessandro Morabito
    Published: April 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00008
    Viewed:1246
    Downloaded:38
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi...
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00005
    Viewed:8491
    Downloaded:461
    Open Access
    Original Article
    Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients
    Aim: Single biomarker diagnostic test of BRAFV600 locus in metastatic melanoma is mandatory for treatment decision; however, multiple-gene based techniques, such as targeted next-generation sequenc ...
    Paola Castillo ... Cristina Teixido
    Published: April 28, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00006
    Viewed:1690
    Downloaded:36
    Open Access
    Editorial
    Exploration of Targeted Anti-tumor Therapy: a contribution to the development of targeted therapies
    Nicola Normanno, Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00001
    Viewed:670
    Downloaded:13
    Open Access
    Review
    Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms
    Cancer development is frequently associated with dysregulation of mRNA translation to enhance both increased global protein synthesis and translation of specific mRNAs encoding oncoproteins. Thus, t...
    Joe Taylor ... Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00002
    Viewed:3555
    Downloaded:100
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of...
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00003
    Viewed:3798
    Downloaded:124
    Open Access
    Review
    Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
    Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The re...
    Anna Maria Rachiglio ... Nicola Normanno
    Published: February 29, 2020 Explor Target Antitumor Ther. DOI: 10.37349/etat.2020.00004
    Viewed:3215
    Downloaded:114